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A Gene for an Autosomal Dominant Scleroatrophic
Syndrome Predisposing to Skin Cancer (Huriez
Syndrome) Maps to Chromosome 4q23
To the Editor:
Huriez syndrome (MIM 181600), also referred to as
“sclerotylosis,” is an autosomal dominant genoderma-
tosis, characterized by the triad of congenital scleroa-
trophy of the distal extremities, palmoplantar kerato-
derma (PPK), and hypoplastic nail changes, that was first
described in two large pedigrees from northern France
(Huriez et al. 1968). Several additional families have
since been described ( Lambert et al. 1977; Fischer 1978;
Shaw et al. 1978; Hamm et al. 1996; Kavanagh et al.
1997). The development of aggressive squamous cell car-
cinoma (SCC) of the affected skin is a distinctive feature
of the syndrome, occurring in ∼15% of affected indi-
viduals. SCC in Huriez syndrome is characterized by
early onset, mostly in the third to fourth decade of life,
and by early metastasis formation (Hamm et al. 1996).
The pathogenetic mechanism of tumorigenesis in Huriez
syndrome is unknown.
Linkage to the MN–blood-type locus on chromosome
4q28-q31 was reported initially and has subsequently
been refuted (Delaporte et al. 1995; Kavanagh et al.
1997). We therefore embarked on a linkage analysis for
Huriez syndrome with highly polymorphic microsatellite
markers, beginning on chromosome 4. After informed
consent was obtained, 22 affected and 35 unaffected
members of one of the families first described by Huriez
(family A) and a second family originating from the same
region of northern France (family B) were included in
the analysis. We calculated two-point LOD scores be-
tween each marker locus and Huriez syndrome, under
the assumption of autosomal dominant inheritance with
complete penetrance, a frequency of .0005 for the dis-
ease allele, and equal allele frequencies for each marker
allele, using the LINKAGE version 5.21 software (La-
throp et al. 1984). With reference to the Human Gene
Map (Schuler et al. 1996), we identified marker D4S424
within 2 cM of the glycophorin A gene (GYPA), which
is the erythrocyte membrane protein that encodes the
MN–blood-group receptors. D4S424 yielded a LOD
score of 10.7 at recombination fraction (v) 0.01. In
the families under investigation, the MN–blood-type lo-
cus was therefore excluded as a candidate region for
Huriez syndrome. Our finding is consistent with the ex-
clusion of the MN locus in the first English family with
Huriez syndrome (Kavanagh et al. 1997). In contrast,
marker D4S1560 gave evidence for linkage, with a LOD
score of 4.4 at . Subsequent analysis of additionalv = 0
flanking markers confirmed localization of the Huriez
locus to this region, with the highest LOD score (Zmax)
of 12.22 at , with D4S2380 (table 1). For fine map-v = 0
ping of the candidate region, additional microsatellite
markers were selected and mapped on the high-resolu-
tion Stanford Human Genome Center TNG radiation
hybrid panel. Relative distances in centirays (fig. 1) were
determined with reference to the Stanford G3 panel
(Stewart et al. 1997).
Under the more conservative assumption of incom-
plete penetrance, the candidate interval is defined by two
recombination events in one affected individual (family
A, member 6.1). Here, the 17-cM region is delimited
centromerically by D4S395 and distally by D4S411.
Under the assumption of complete penetrance, two ad-
ditional recombination events in two unaffected pro-
bands further limit the Huriez locus (fig. 2): one in family
A (member 4.11), localizing the gene telomeric to
D4S1544, and the other in family B (member 2.5), lo-
calizing the gene centromeric to D4S2966. The Huriez
locus is thus confined to an 8-cM region between
D4S1544 and D4S2966. Haplotypes were constructed
for both families by use of 16 markers between D4S2963
and D4S1564. Comparison between the disease alleles
of the two families revealed three adjacent markers iden-
tical by state (IBS) (fig. 1). For two of these markers,
D4S2973 and D4S1559, the shared allele is the most
common allele found among all individuals, with relative
frequencies of .87 and .58, respectively. There is no
known relationship between the two families investi-
gated. However, in view of the rarity of the condition
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Table 1
Combined Pairwise LOD Scores for Families A and B between Huriez Syndrome and Markers
on Chromosome 4q
MARKER
CM
FROM
PTEL
LOD SCORE AT v =
Zmax vmax.0 .01 .05 .1 .2 .3 .4
D4S1544 97.9  6.36 6.55 6.16 4.93 3.35 1.52 6.55 .05
D4S414 99.2 6.99 6.87 6.39 5.76 4.40 2.97 1.26 6.87 .0
D4S2909 100.0 8.41 8.27 7.66 6.87 5.17 3.29 1.35 8.41 .0
D4S2380 101.0 12.22 12.02 11.19 10.10 7.75 5.16 2.39 12.22 .0
D4S2973 103.1 .86 .85 .78 .70 .51 .31 .13 .86 .0
D4S1559 103.1 3.69 3.59 3.21 2.76 1.91 1.08 .32 3.69 .0
D4S1578 103.1 6.67 6.55 6.04 5.40 4.08 2.71 1.29 6.67 .0
D4S1560 103.1 4.40 4.32 3.99 3.56 2.64 1.63 .60 4.32 .0
D4S2986 104.6 9.96 9.81 9.19 8.36 6.53 4.45 2.12 9.81 .0
D4S2966 107.8  8.48 8.51 7.93 6.30 4.32 2.09 8.51 .01
D4S424 146.4  10.73 3.60 1.02 .73 .92 .40 .92 .3
NOTE.—Marker coordinates are noted according to the final Ge´ne´thon linkage map (Dib et al.
1996). The coordinate of D4S2380 is noted with reference to the Marshfield Comprehensive Human
Genetic Maps (Broman et al. 1998). D4S424 maps within 2 cM of the glycophorin A gene (GYPA,
MN–blood-group receptors).
and the fact that both families originate from neigh-
boring villages in northern France, we inferred that the
IBS status of three adjacent markers in the candidate
region reflects the existence of a common founder hap-
lotype. If the common haplotype is verified, this would
indicate that the Huriez gene is located in a 3.1-cM
interval between D4S2909 and D4S1578. Further mark-
ers must be investigated to substantiate this finding, al-
though we have exhausted all known microsatellite
markers in this region. In both families, Huriez syn-
drome is linked to markers on chromosome 4q some 30
cM centromeric of D4S424. Epidermal growth factor
(EGF) was a potential candidate gene that has been
mapped to chromosome 4q21-24 on a human-rodent
somatic cell hybrid panel (Brissenden et al. 1984). EGF
induces cellular proliferation and differentiation of var-
ious epidermal and epithelial tissues and is a potent mi-
togen (Carpenter and Cohen 1979). Increased levels of
the EGF receptor are associated with malignant trans-
formation of squamous cells (Lee et al. 1997) and are
observed in SCC of the skin (Springer and Robinson
1991), esophagus (Yano et al. 1991), head and neck (Lee
et al. 1997), cervix (Kim et al. 1996), and lung (Pfeiffer
et al. 1998). According to the gene map of the human
genome (Schuler et al. 1996), the EGF gene is located
between D4S411 and D4S1564. Haplotype analysis for
both families A and B revealed recombination events in
individuals 6.1 and 2.5, respectively, that exclude EGF
as a candidate gene for Huriez syndrome.
Affected patients with sclerotylosis have a greatly in-
creased risk of cutaneous SCC. The clinical presentation
of patients with sclerotylosis strongly indicates that this
disorder is a precancerous condition. Affected individ-
uals carry a 1100-fold higher risk for the development
of aggressive SCC of the skin (Levi et al. 1995; Gray et
al. 1997), the age at onset of skin cancer is much lower
than in the general population, and tumors arise in areas
of affected skin. Sclerosis (Nachbar et al. 1993; Ozturk
et al. 1998), atrophy, and scarring (Hagiwara et al.
1996) are well-recognized risk factors for the develop-
ment of SCC of the skin. Clinically, the development of
SCC in Huriez syndrome bears striking similarity to
Marjolin’s ulcer, which refers to malignancies arising in
chronic ulcers of the skin, scar tissue, and burn scars
(Fleming et al. 1990). The skin fragility found in Huriez
syndrome leads to scarring, and the scleroatrophic
changes may represent a process similar to scarring, thus
predisposing to skin cancer. In addition, the exposure to
exogenous mutagens such as arsenic (Jackson and Gra-
inge 1975) have been recognized as risk factors for the
development of SCC of the skin. The atrophic changes
in skin anatomy observed in this type of PPK may disturb
the barrier function of the skin, thus facilitating the pen-
etration of putative physical, chemical, and infectious
mutagens. However, most PPKs are not associated with
an increased risk of skin cancer (Stevens et al. 1996). In
addition, there is no evidence that sclerotylosis is asso-
ciated with an increased risk of skin tumors other than
SCC, which one would expect to observe if the devel-
opment of local malignancies were solely attributable to
the defective barrier function and the increased exposure
to exogenic carcinogens.
It is noteworthy that loss of heterozygosity of 4q has
been reported in 81% of squamous cell neoplasms of
the head and neck (Pershouse et al. 1997) and in 46%
of cervical carcinoma (Mitra et al. 1994). In SCC of the
head and neck with deletions on 4q, the region that was
consistently involved extends distal of the Huriez gene
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Figure 2 Linkage map of microsatellite markers from chro-
mosome 4q23. Genetic distances are indicated in centimorgans. Mark-
ers are arranged in map order according to the final Ge´ne´thon human
linkage map (Dib et al. 1996). In the candidate region, markers are
ordered according to their score on the TNG radiation hybrid panel.
Here, relative positions are noted in cR after assigning 0 cR to marker
D4S1544. The wild-type allele is represented by a white bar, the mu-
tated allele by a gray bar. In the candidate region, markers IBS are
noted in boldface type. The recombination events in members 4.11
and 6.1 of family 1 and 2.5 of family 2 are shown. The minimal
candidate region for Huriez syndrome is marked. “aff.” indicates af-
fected; “not aff.,” not affected.
locus and possibly overlaps with it on its centromeric
end. A tumor-progression model for SCC of the skin has
been proposed in which serial mutagenesis exceeds a
threshold level, leading to tumor growth (Grossman and
Leffell 1997). The gene mutation underlying Huriez syn-
drome may represent a first event in that series. Iden-
tification and characterization of the gene causing Hu-
riez syndrome may provide important insights into the
pathogenesis of skin cancer.
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Transmission-Ratio Distortion at Xp11.4-p21.1 in Type
1 Diabetes
To the Editor:
Naumova et al. (1998) reported a deviation from the
expected Mendelian 1:1 ratio of grandpaternal/grand-
maternal alleles at loci in Xp11.4-p21.1 in the children
of 47 families not selected on the basis of the disease
status of the children. The transmission-ratio distortion
(TRD) was found only among male offspring and was
manifested as a bias in favor of the inheritance of the
alleles of the maternal grandfather. The critical region,
containing the putative TRD locus, named “DMS1,”
was mapped to an interval bounded by DXS538 and
DXS7 and peaking at DXS1068.
These observations might have an impact on the re-
sults of a study in which we have provided evidence of
linkage to type 1 diabetes mellitus (MIM 222100), in
the same region of chromosome X (Cucca et al. 1998).
The possibility of TRD at chromosome Xp gives rise to
the question of whether the diabetes-linkage results are
indeed disease specific. The following evidence suggests
that it is highly unlikely that the DMS1 locus is respon-
sible for the chromosome Xp linkage to type 1 diabetes.
We genotyped DXS1068 (a marker that was at the
peak of our linkage curve) in two sample sets of control
families not ascertained on the basis of the disease status
of the children. These control families were from the
Centre d’Etude du Polymorphisme Humaine (Fondation
Jean Dausset/CEPH) and from a population-based sam-
